Chaouch Mohamed Ali, Mazzotta Alessandro, da Costa Adriano Carneiro, Hussain Mohammad Iqbal, Gouader Amine, Krimi Bassem, Panaro Fabrizio, Guiu Boris, Soubrane Olivier, Oweira Hani
Department of Visceral and Digestive Surgery, Fattouma Bourguiba Hospital, University of Monastir, Monastir, Tunisia.
Department of Visceral and Digestive Surgery, Institute Mutualist of Montsouris, University of Paris, Paris, France.
Front Med (Lausanne). 2024 Jan 10;10:1334661. doi: 10.3389/fmed.2023.1334661. eCollection 2023.
This systematic review aimed to compare liver venous deprivation (LVD) with portal vein embolization (PVE) in terms of future liver volume, postoperative outcomes, and oncological safety before major hepatectomy.
We conducted this systematic review and meta-analysis following the PRISMA guidelines 2020 and AMSTAR 2 guidelines. Comparative articles published before November 2022 were retained.
The literature search identified nine eligible comparative studies. They included 557 patients, 207 in the LVD group and 350 in the PVE group. This systematic review and meta-analysis concluded that LVD was associated with higher future liver remnant (FLR) volume after embolization, percentage of FLR hypertrophy, lower failure of resection due to low FLR, faster kinetic growth, higher day 5 prothrombin time, and higher 3 years' disease-free survival. This study did not find any difference between the LVD and PVE groups in terms of complications related to embolization, FLR percentage of hypertrophy after embolization, failure of resection, 3-month mortality, overall morbidity, major complications, operative time, blood loss, bile leak, ascites, post hepatectomy liver failure, day 5 bilirubin level, hospital stay, and three years' overall survival.
LVD is as feasible and safe as PVE with encouraging results making some selected patients more suitable for surgery, even with a small FLR.
The review protocol was registered in PROSPERO before conducting the study (CRD42021287628).
本系统评价旨在比较肝静脉阻断(LVD)与门静脉栓塞(PVE)在大肝切除术前对未来肝体积、术后结局及肿瘤学安全性的影响。
我们按照2020年PRISMA指南和AMSTAR 2指南进行了本系统评价和荟萃分析。纳入2022年11月之前发表的比较性文章。
文献检索确定了9项符合条件的比较性研究。共纳入557例患者,其中LVD组207例,PVE组350例。本系统评价和荟萃分析得出结论,LVD与栓塞后更高的未来肝残余(FLR)体积、FLR肥大百分比、因FLR低导致的切除失败率降低、更快的动态生长、术后第5天更高的凝血酶原时间以及更高的3年无病生存率相关。本研究未发现LVD组和PVE组在栓塞相关并发症、栓塞后FLR肥大百分比、切除失败、3个月死亡率、总体发病率、主要并发症、手术时间、失血量、胆漏、腹水、肝切除术后肝功能衰竭、术后第5天胆红素水平、住院时间及3年总生存率方面存在差异。
LVD与PVE同样可行且安全,其令人鼓舞的结果使一些选定的患者更适合手术,即使FLR较小。
在开展本研究之前,该评价方案已在PROSPERO中注册(CRD42021287628)。